JIP
ITCI

Jaffetilchin Investment Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jaffetilchin Investment Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,972
Closed -$392K – 467
2025
Q1 		$392K Sell
2,972
-2,224
-43% -$277K 0.03% 276
2024
Q4 		$434K Hold
5,196
– – 0.03% 252
2024
Q3 		$380K Hold
5,196
– – 0.03% 258
2024
Q2 		$356K Sell
5,196
-250
-5% -$17.3K 0.03% 263
2024
Q1 		$377K Sell
5,446
-100
-2% -$6.87K 0.03% 253
2023
Q4 		$397K Sell
5,546
-800
-13% -$46K 0.04% 245
2023
Q3 		$331K Sell
6,346
-185
-3% -$10.8K 0.04% 250
2023
Q2 		$414K Sell
6,531
-190
-3% -$11.8K 0.04% 225
2023
Q1 		$364K Buy
6,721
+185
+3% +$8.95K 0.04% 251
2022
Q4 		$346K Sell
6,536
-23,700
-78% -$1.19M 0.04% 247
2022
Q3 		$1.41M Sell
30,236
-467
-2% -$24.4K 0.18% 79
2022
Q2 		$1.75M Sell
30,703
-638
-2% -$36.2K 0.21% 85
2022
Q1 		$1.73M Sell
31,341
-864
-3% -$44.9K 0.2% 75
2021
Q4 		$1.69M Sell
32,205
-11,575
-26% -$486K 0.16% 93
2021
Q3 		$1.63M Sell
43,780
-47,158
-52% -$1.64M 0.17% 90
2021
Q2 		$3.32M Buy
90,938
+47,197
+108% +$1.74M 0.23% 82
2021
Q1 		$1.48M Sell
43,741
-188
-0.4% -$6.52K 0.17% 108
2020
Q4 		$1.4M Buy
+43,929
New +$1.15M 0.2% 84

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Jaffetilchin Investment Partners's ITCI Position: Q2 2025 in Review

Jaffetilchin Investment Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,972 shares — an estimated $392K sold.

Jaffetilchin Investment Partners first reported a position in ITCI in Q4 2020 and held it in 18 quarters. The position peaked at $3.32M in Q2 2021. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Jaffetilchin Investment Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 2,972 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $392K.
  • Jaffetilchin Investment Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 18 quarters.
  • Jaffetilchin Investment Partners's Intra-Cellular Therapies Inc. position peaked at $3.32M in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Jaffetilchin Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.